Turkish BRIEF version of the Hammersmith Infant Neurological Examination (HINE)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational project implements a Turkish translation of the BRIEF-HINE and uses it with infants identified as high risk for neurological impairment. Clinicians will administer the brief HINE during routine follow-up visits and collect findings alongside standard clinical information and outcomes. The study will measure the tool's reliability, feasibility in busy clinics, and ability to flag infants who need early intervention. The goal is to produce a validated, shorter neurological exam that is practical for use in resource-limited follow-up programs.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Infants with high risk of CP: Periventricular hemorrhage, intracranial hemorrhage grade 2, 3, 4, cystic PVL, stage 3 hypoxic ischemic encephalopathy, neonatal bilirubin encephalopathy (kernicterus), perinatal stroke, perinatal asphyxia, respiratory distress syndrome (RDS), bronchopulmonary dysplasia (BPD) and infants receiving long-term O₂ support, sepsis due to gram-negative bacteria, necrotizing enterocolitis (NEC), infantile apnea, those with a low 5-minute Apgar score (3 and below), those diagnosed with intrauterine growth retardation, multiple births (twins, triplets), preterm infants with retinopathy of prematurity (ROP), infants with prolonged severe hypoglycemia and hypocalcemia, (small for gestational age (SGA), less than the 3rd percentile) or large for gestational age (large for gestational age (LGA), less than the 97th percentile). (large) babies, babies receiving mechanical ventilation for more than 24 hours, babies born at less than 32 weeks of gestation and weighing less than 1500 grams.

Exclusion Criteria:

* Infants with any known orthopedic, systemic disease or neurological diagnosis other than CP

Where it's running

• Kahramanmaraş Sütçü imam University
  Kahramanmaraş, Onikişubat, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Hatice adıgüzel tat, Associate Proffessor
• Email: fzthatis@gmail.com
• Phone: +90 344 300 26 47

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Micronutrient Enhancement for Development and Health in Adolescent Girls

  This study tests whether daily micronutrient supplements (MMS or MMS+), compared with weekly iron-folic acid, can improve school performance and growth in 10- to 18-year-old girls in rural Bangladesh.

  Recruiting Phase 3 Johns Hopkins Bloomberg School of Public Health · Rangpur City · NCT07695883

• Hospital-to-home support (H-HOPE) for infants with congenital defects after neonatal surgery and their parents

  This program tests whether H-HOPE helps infants born with congenital defects who need neonatal surgery — and their parents — improve feeding, growth, early development, and parental mental health.

  Recruiting Ann & Robert H Lurie Children's Hospital of Chicago · Chicago, Illinois · NCT07372898

• MOM-CARE: enhanced micronutrient supplements during and after pregnancy to help babies be born healthier and grow better

  This will test whether an enhanced multivitamin supplement (MMS Plus) given during pregnancy and after birth helps babies born to women in peri-urban Karachi have better birth outcomes and faster early growth than standard MMS or iron/folic acid.

  Recruiting Phase 3 Aga Khan University · Karachi, Sindh · NCT07029282

• Using ZetaFuse Bone Graft to treat cervical disc disease

  This study is testing if a new bone graft called ZetaFuse can help people with neck problems feel better and improve their nerve function after surgery.

  Recruiting at 2 sites Zetagen Therapeutics, Inc · Randwick, New South Wales and 1 other locations · NCT05971329

• Nurse-led program to improve sleep for children with cancer

  This program will test whether nurse-led sleep education plus relaxation and breathing exercises can improve sleep for Chinese-speaking children aged 6–12 who are receiving cancer treatment.

  Recruiting Chinese University of Hong Kong · Kowloon Bay · NCT07323069

• Using AMH levels to predict infertility risk in children with cancer

  This study is trying to see if measuring a hormone called AMH can help predict the risk of infertility in children with cancer who are starting treatment.

  Recruiting at 8 sites Erasme University Hospital · Montegnée, Liège and 7 other locations · NCT02595255

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.